Ranibizumab no better than saline for vitreous hemorrhage

Ranibizumab no better than saline for vitreous hemorrhage
For patients with vitreous hemorrhage from proliferative diabetic retinopathy, the probability of vitrectomy within 16 weeks after intravitreal injections of ranibizumab or saline is lower than expected, with little difference seen between the two treatments, according to a study published online Jan. 31 in JAMA Ophthalmology.

(HealthDay)—For patients with vitreous hemorrhage from proliferative diabetic retinopathy (PDR), the probability of vitrectomy within 16 weeks after intravitreal injections of ranibizumab or saline is lower than expected, with little difference seen between the two treatments, according to a study published online Jan. 31 in JAMA Ophthalmology.

Abdhish R. Bhavsar, M.D., from the Retina Center of Minnesota in Minneapolis, along with colleagues from the Clinical Research Network, compared intravitreal ranibizumab with intravitreal saline injections for their effect on vitrectomy rates for vitreous hemorrhage from PDR in a phase 3, randomized clinical trial involving 261 eyes of 261 participants who were at least 18 years of age and had type 1 or 2 diabetes. One hundred twenty-five eyes were randomly allocated to receive 0.5-mg intravitreal ranibizumab, and 136 were randomized to receive intravitreal saline at baseline and at four and eight weeks.

At 16 weeks, the researchers found that the cumulative probability of vitrectomy was 12 percent with ranibizumab and 17 percent with saline, and that the cumulative probability of complete panretinal photocoagulation without vitrectomy was 44 and 31 percent, respectively (P = 0.05). From baseline to 12 weeks, the mean improvement was 22 and 16 letters, respectively (P = 0.04). Within 16 weeks, 6 and 17 percent, respectively, experienced recurrent vitreous hemorrhage (P = 0.01). Endophthalmitis developed in one eye following .

"This study suggests little likelihood of a clinically important difference between ranibizumab and saline on the rate of vitrectomy by 16 weeks in eyes with vitreous hemorrhage from PDR," the authors write. "Whether vitrectomy rates after saline or ranibizumab injection are different than observation alone cannot be determined from this study."

provided the and partially funded the study.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Long-term ranibizumab beneficial for macular edema

Oct 11, 2012

(HealthDay)—Long-term aggressive treatment of patients with macular edema with ranibizumab during a third year correlates with reduced mean foveal thickness (FTH) and improved best-corrected visual acuity ...

Steroid injections may slow diabetes-related eye disease

Dec 15, 2009

Injecting the corticosteroid triamcinolone into the eye may slow the progression of diabetic retinopathy, a complication of diabetes that can cause vision loss and blindness, according to a report in the December issue of ...

Vitreolytic ocriplasmin resolves vitreomacular traction

Aug 16, 2012

(HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse ...

Recommended for you

Simple test could detect serious eye condition early

Aug 28, 2014

A simple colour test that could detect the early onset of a condition which accounts for over half of visual impairment certifications in the UK is being researched by scientists at Aston University.

Yellow pigment in eye may aid vision through haze

Aug 25, 2014

Individuals with greater amounts of yellow pigment in the eye may be better able to see distant objects in hazy conditions, suggests a study in the September issue of Optometry and Vision Science, official journal of the A ...

New DNA test for diagnosing diseases linked to childhood blindness

Aug 21, 2014

Researchers in the United Kingdom have demonstrated that advanced DNA testing for congenital cataracts can quickly and accurately diagnose a number of rare diseases marked by childhood blindness, according to a study published online today in Ophthalmology, the journal of the American Academy o ...

User comments